Comprehensive Management of Inflammatory Bowel Disease: What's Next.

Diagnosed VTE rates were similar between patients with an IBD-related and a non IBD-related hospitalization. In the last 20 years, the treatment and management of patients with Crohn's disease (CD) and ulcerative colitis (UC) have been revolutionized by the introduction of biological therapies and small molecules. Interestingly, in patients with UC, the dose intensification's requirement rate was significantly higher compared to CD perhaps due to disease severity and accelerated anti-TNF clearance in active UC, warranting higher drug concentrations. Overall, the studies in this Special Issue provide a comprehensive view on novel therapeutic strategies in IBD and will assist physicians in improving IBD care and attempt to tailor the right treatment for each patient. [Extracted from the article]